Lyell Immunopharma, Inc.
LYEL
$9.69
$0.262.76%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -334.52M | -342.99M | -203.99M | -210.26M | -228.34M |
| Total Depreciation and Amortization | 18.05M | 19.63M | 19.66M | 20.09M | 20.25M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 150.80M | 164.09M | 29.97M | 31.79M | 44.10M |
| Change in Net Operating Assets | -9.44M | -3.12M | -1.43M | -43.00K | 4.50M |
| Cash from Operations | -175.12M | -162.39M | -155.79M | -158.43M | -159.50M |
| Capital Expenditure | -680.00K | -464.00K | -445.00K | -581.00K | -1.18M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -31.35M | -31.35M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 201.92M | 154.23M | -31.33M | 66.56M | 175.07M |
| Cash from Investing | 169.90M | 122.42M | -31.77M | 65.98M | 173.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.30M | 1.40M | 1.85M | 1.92M | 2.30M |
| Repurchase of Common Stock | 0.00 | -76.00K | -199.00K | -414.00K | -464.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.00K | -- | -- | -- | -- |
| Cash from Financing | 1.30M | 1.33M | 1.65M | 1.51M | 1.84M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.92M | -38.64M | -185.91M | -90.94M | 16.23M |